Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Peripheral blood stem cells (PBSC) are hematopoietic progenitor cells collected from the donor's blood after mobilization (typically with G-CSF). In the context of the HAMLET trial (NCT04366206) led by DKMS gemeinnützige GmbH, these cells are used for allogeneic hematopoietic cell transplantation in patients with high-risk acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or myelodysplastic syndromes (MDS). The study compares outcomes between transplants from partially matched unrelated donors (MMUD) and haploidentical donors, both utilizing post-transplant cyclophosphamide (PTCy) to mitigate graft-versus-host disease (GvHD). The primary therapeutic goal is the restoration of the recipient's hematopoietic system and the induction of a graft-versus-leukemia (GvL) effect to prevent disease relapse.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Peripheral blood stem cells (DKMS).